SCHEMBL5605322

SCHEMBL5605322

CN1CCN(S(=O)(=O)c2ccc3c(c2)C(=O)c2ccccc2C3=O)CC1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.59
TSHR P16473 3/20 0.59
PKM P14618 1/20 0.58
ATM Q13315 1/20 0.54
APOBEC3A P31941 1/20 0.54
APOBEC3G Q9HC16 1/20 0.54
CASP1 P29466 1/20 0.54
CASP7 P55210 1/20 0.54
HSD17B10 Q99714 1/20 0.54
HTT P42858 2/20 0.54
MAPK1 P28482 1/20 0.53
LMNA P02545 1/20 0.53
USP2 O75604 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
RAB9A P51151 1/20 0.52
KDM4E B2RXH2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1684564 0.81 TSHR (0.67) POLBSMN1; SMN2TSHRPKMATM
SCHEMBL16026507 0.80 ATM (0.58) POLBSMN1; SMN2TSHRPKMATM
SCHEMBL54427 0.79 USP2 (0.66) POLBSMN1; SMN2TSHRATMCASP1
SCHEMBL3407424 0.79 USP2 (0.66) POLBSMN1; SMN2TSHRATMCASP1
SCHEMBL3405913 0.79 USP2 (0.66) POLBSMN1; SMN2TSHRATMCASP1
SCHEMBL3406366 0.79 USP2 (0.66) POLBSMN1; SMN2TSHRATMCASP1
SCHEMBL15014129 0.78 PKM (0.89) POLBSMN1; SMN2TSHRPKMHTT
SCHEMBL3936569 0.77 POLB (1.00) POLBSMN1; SMN2TSHRPKMATM
SCHEMBL28086690 0.77 CASP7 (0.53) POLBSMN1; SMN2TSHRATMCASP1
SCHEMBL20302795 0.76 KDM4E (0.69) POLBSMN1; SMN2TSHRATMCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377536-A4 SELF-REDUCING ANTHRAQUINONE COMPOUNDS COMMW SCIENT AND RES ORGANISAT (AU) 2007-02-28 EP claimed
US-20040175314-A1 Self-reducing anthraquinone compounds COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORAGNISATION (AU) 2004-09-09 US claimed
EP-1377536-A1 SELF-REDUCING ANTHRAQUINONE COMPOUNDS Commonwealth Scientific and Research Organisation (AU) 2004-01-07 EP claimed
WO-2002076916-A1 SELF-REDUCING ANTHRAQUINONE COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2002-10-03 WO claimed
EP-1377536-A4 SELF-REDUCING ANTHRAQUINONE COMPOUNDS COMMW SCIENT AND RES ORGANISAT (AU) 2007-02-28 EP disclosed
US-20040175314-A1 Self-reducing anthraquinone compounds COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORAGNISATION (AU) 2004-09-09 US disclosed
EP-1377536-A1 SELF-REDUCING ANTHRAQUINONE COMPOUNDS Commonwealth Scientific and Research Organisation (AU) 2004-01-07 EP disclosed
WO-2002076916-A1 SELF-REDUCING ANTHRAQUINONE COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040175314-A1 Self-reducing anthraquinone compounds XDH, SQOR, NQO1 POLB 744/4885SMN1; SMN2 3801/4885TSHR 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.